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The most powerful iNKT cell antigen is a-galactosylceramide (a-GalCer), derived from the marine sponge.
However, a-anomeric glycolipids are thought to be absent in mammals. In this issue of Immunity, Kain
et al., (2014) demonstrate the presence of mammalian a-linked glycosylceramides, such as a-GalCer.Innate-like T lymphocytes are able
to rapidly respond to stimulation with
the production of cytokines and other
effector functions (Bendelac et al.,
2007). Part of this group are invariant
natural killer T (iNKT) cells, which express
a restricted T cell receptor (TCR) reper-
toire and molecules associated with NK
cells (Bendelac et al., 2007). The immedi-
ate mode of action of iNKT cells endows
them with regulatory properties regarding
innate and adaptive immune responses.
Therefore, iNKT cells are involved in
many disease processes from infec-
tion to cancer (Bendelac et al., 2007).
In contrast to major-histocompatibility-
complex-restricted T cells recognizing
peptides, iNKT cells react with lipid anti-
gens presented by CD1d molecules
on the surface of antigen-presenting
cells (APCs). The first iNKT cell antigen
described was a-galactosylceramide
(a-GalCer), initially derived from a marine
sponge (Kawano et al., 1997). More-
over, several microbial species produce
a-anomeric glycolipid antigens (Mattner
et al., 2005; Kinjo et al., 2006). To compli-
cate matters, there is evidence that iNKT
cells also recognize endogenous lipids
(Chiu et al., 2002), and indeed, over the
years several self-antigens with rather
weak antigenicity have been proposed
(Zhou et al., 2004; Brennan et al., 2011).
However, current opinion holds that
mammalian hosts are not able to synthe-
size glycosylceramides with the proximal
sugar in an a-glycosidic bond. Notably,
in this issue of Immunity, Kain et al.
(2014) demonstrate the presence of
mammalian a-linked glycosylceramides,
such as a-GalCer. Thus, the most power-
ful iNKT cell antigen, considered to be
exclusively exogenous in nature, couldbe the long-searched-for endogenous
antigen after all.
A recent report demonstrated that the
abundant self-lipid b-glucosylceramide
(b-GluCer) serves as endogenous antigen
for iNKT cell activation (Brennan et al.,
2011). Kain et al. have now synthesized
highly pure b-GluCer and found that it
failed to stimulate iNKT cells. Then they
tested commercially available b-GluCer
from different sources, which restored
iNKT cell activation. Subsequently, the
authors treated those samples with the
enzyme b-glucocerebrosidase (GBA) in
order to fully digest b-GluCer. Surpris-
ingly, the iNKT cell stimulatory capacity
of the lipid samples did not change after
substrate digestion. Thus, Kain et al.
have shown that b-GluCer is not a veri-
table antigen and that minute contami-
nations with stimulatory lipid entities can
trigger activation of iNKT cells.
Following the idea of a possible role for
a-linked glycolipids as endogenous anti-
gens, the authors investigated the impact
of a CD1d-a-GalCer antibody (L363) in
functional iNKT cell experiments. In this
context, autoreactivity of iNKT lympho-
cytes is known as the T cell response to
APCs without the addition of exogenous
lipid antigens (Bendelac et al., 2007).
Interestingly, L363 antibody was able
to abrogate the T cell response to un-
treated APCs, suggesting that endo-
genous a-linked glycosylceramides were
present during antigen presentation.
Next, Kain et al. studied the L363 anti-
body tool in depth by performing elegant
affinity studies of CD1d-glycolipid recog-
nition by surface plasmon resonance.
Accordingly, L363 bound a-GalCer and
a-GluCer in complex with CD1d mole-
cules, although with lower affinity for theImmunity 41latter. By contrast, L363 failed to recog-
nize any b-linked glycosylceramides in
complex with CD1d.
Subsequently, the CD1d-a-GalCer-
specific antibody was used for immu-
noprecipitation of lipid complexes with
CD1d in a dendritic cell (DC) line and
CD1d transfectants (rat basophilic leuke-
mia [RBL] cell line). Immunoprecipitates
were analyzed by multiple reaction moni-
toring mass spectrometry and revealed
a peak corresponding to standard C24:1
a-GalCer. These findings suggested
the presence of monoglycosylceramides
bound to CD1d in mammalian APC lines.
However, the quantity of material recov-
ered by immunoprecipitation was not
sufficient for functional iNKT cell experi-
ments. For the same reasons, the deter-
mination of a- and b-anomers by nuclear
magnetic resonance (NMR) was also not
possible.
To overcome that obstacle, Kain
et al. succeeded in generating an
a-GalCer-specific antibody to be used
for lipid immunoprecipitation. For this
purpose, RBL-CD1d cells were metaboli-
cally labeled with C14-UDP-galactose
prior to precipitation with anti-a-GalCer.
Subsequently, immunoprecipitates were
analyzed by thin-layer chromatography
(TLC), which revealed a band that
migrated at the height of reference
C24:1 a-GalCer. As a prerequisite, Kain
et al. established a TLC system that
allows for the migratory separation of
galactosylceramides only differing in their
a- or b-anomeric configuration. Although
this is not direct proof by NMR, the TLC
results make the presence of endogenous
a-GalCer likely.
Furthermore, the authors examined
a mechanism by which the availability, October 16, 2014 ª2014 Elsevier Inc. 505
Figure 1. Role of Endogenous a-Glycosylceramides in iNKT Cell Activation
Left panel: synthesis and degradation of endogenous a-glycosylceramides. b-GalCer or b-GluCer
synthesized by CGT or GCS, respectively, could be converted into a-glycolipids by a putative anomerase.
Alternatively, a-glycosylceramides could be generated directly by the addition of a-galactose or a-glucose
onto ceramides by unfaithful CGT or GCS. The newly generated a-glycolipids can then either be loaded
onto CD1d molecules and activate iNKT cells or undergo degradation. First, ASAH1 cuts glycosylcera-
mides into fatty acids and a-psychosine or a-glucopsychosine. GLA or GAA can subsequently digest
them into sugars and sphingosines.
Right panel: induced accumulation of endogenous antigen upon degradation block. Blocking the enzymes
in the degradation pathway results in accumulation of a-glycosylceramides. This accumulation leads to
enhanced antigen presentation and increased iNKT cell activation.
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Previewsof endogenous a-glycosylceramides is
regulated. A previous study established
the concept of threshold control, in which
catabolic enzymes degrade endoge-
nous lipid antigens under steady-state
conditions and thus preclude efficient
loading on CD1d and subsequent iNKT
cell activation (Darmoise et al., 2010).
Upon enzyme block in the degradative
pathway, endogenous antigen accumu-
lates and reaches a threshold for produc-
tive CD1d loading and stimulation of iNKT
cells (Darmoise et al., 2010). Accordingly,
a-galactosidase A (GLA) is able to cleave
the terminal a-linked galactose from gly-
colipids such as globotriaosylceramide
(Gb3), iGb3, and galabiaosylceramide.
However, it remains unclear how GLA
could regulate a-GalCer given that the
enzyme is not capable of acting on the
proximal a-galactose bound to ceramide.
Kain et al. provide a solution to this prob-
lem. Accordingly, a two-step mechanism
can regulate the abundance of endo-
genous a-glycosylceramides (Figure 1).506 Immunity 41, October 16, 2014 ª2014 ElFirst, acid ceramidase (ASAH1) removes
the acyl chain, which leaves the sugar
group connected to sphingosine and
thus creates a-psychosine (or a-glucop-
sychosine). Second, GLA is now able to
access a-psychosine for degradation to
sphingosine and sugar (acid a-glucosi-
dase [GAA] could replaceGLAwith regard
to a-GluCer degradation). Thus, inhibition
of GLA and/or ASAH1 can regulate the
accumulation of endogenous a-GalCer
for activation of iNKT cells (Figure 1).
The study by Kain et al. lays the founda-
tions for future challenges to elucidate
the biological role of endogenous a-gly-
cosylceramides. This will include the
refinement of chemical and biochemical
techniques in order to directly prove the
a-anomeric entity by NMR. Improving
the yield of endogenous a-GalCer will
also facilitate functional antigen-pre-
sentation experiments to demonstrate
its bioactivity. Another critical task
would involve the isolation of endogenous
a-glycosylceramides from mammaliansevier Inc.host tissues. Taken together, these future
achievements will allow the assessment
of the in vivo role of endogenous a-GalCer
and a-GluCer.
Ultimately, every interesting study
leads to new questions to be answered.
In this context, which synthetic pathway
promotes the generation of endogenous
a-glycosylceramides? Maybe new en-
zymes that directly synthesize a-GalCer
and a-GluCer will be discovered. In anal-
ogy to ceramide galactosyltransferase
(CGT) and glucosylceramide synthase
(GCS), which produce corresponding
b-forms, one could propose the existence
of CaGT and aGCS, respectively. Alter-
natively, the known enzymes CGT and
GCS could work in an unfaithful fashion
and generate minute amounts of the
respective a-forms (Figure 1). Finally,
we postulate the presence of glucose- or
galactose-dependent anomerases that
mediate the conversion of b-glycosylcer-
amides into endogenous a-GluCer or
a-GalCer for the development and activa-
tion of iNKT cells.
REFERENCES
Bendelac, A., Savage, P.B., and Teyton, L. (2007).
Annu. Rev. Immunol. 25, 297–336.
Brennan, P.J., Tatituri, R.V., Brigl, M., Kim, E.Y.,
Tuli, A., Sanderson, J.P., Gadola, S.D., Hsu, F.F.,
Besra, G.S., and Brenner, M.B. (2011). Nat. Immu-
nol. 12, 1202–1211.
Chiu, Y.H., Park, S.H., Benlagha, K., Forestier, C.,
Jayawardena-Wolf, J., Savage, P.B., Teyton, L.,
and Bendelac, A. (2002). Nat. Immunol. 3, 55–60.
Darmoise, A., Teneberg, S., Bouzonville, L., Brady,
R.O., Beck, M., Kaufmann, S.H., and Winau, F.
(2010). Immunity 33, 216–228.
Kain, L., Webb, B., Anderson, B.L., Deng, S., Holt,
M., Constanzo, A., Zhao, M., Self, K., Teyton, A.,
Everett, C., et al. (2014). Immunity 41, this issue,
543–554.
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko,
Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H.,
Kondo, E., et al. (1997). Science 278, 1626–1629.
Kinjo, Y., Tupin, E., Wu, D., Fujio, M., Garcia-Nav-
arro, R., Benhnia, M.R., Zajonc, D.M., Ben-Menac-
hem, G., Ainge, G.D., Painter, G.F., et al. (2006).
Nat. Immunol. 7, 978–986.
Mattner, J., Debord, K.L., Ismail, N., Goff, R.D.,
Cantu, C., 3rd, Zhou, D., Saint-Mezard, P., Wang,
V., Gao, Y., Yin, N., et al. (2005). Nature 434,
525–529.
Zhou, D., Mattner, J., Cantu, C., 3rd, Schrantz, N.,
Yin, N., Gao, Y., Sagiv, Y., Hudspeth, K., Wu, Y.P.,
Yamashita, T., et al. (2004). Science 306, 1786–
1789.
